Presentation Description:
This presentation provided an overview of genetic predispositions to specific diseases, as well as the therapies and theories currently being investigated.
Speaker:
John M. Maris, MD
Giulio D’Angio Professor of Pediatrics
Director, Center for Childhood Cancer Research
Children’s Hospital of Philadelphia, Philadelphia
Presentation Description: Graft versus host disease (GVHD) remains the major complication of allogeneic bone marrow transplantation (BMT), but until recently there have been no laboratory biomarkers for GVHD. One new plasma biomarker for GVHD of the gastrointestinal tract, Regenerative 3c (REG3o), has significant diagnostic and prognostic value. This presentation described one approach to the discovery and validation of such biomarkers and analyzed their potential for use in developing new grading schemes with improved risk-stratification of patients.
Speaker:
James L.M. Ferrara, MD, DSc.
Director
Combined Adult and Pediatric Blood and Marrow Transplant Program
University of Michigan Cancer Center, Michigan, USA
Presentation Description: This session provided an overview of four late effects research studies, funded by CIHR (Canadian Institutes of Health Research):
1) Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors: N-PhenoGENICS
2) Preventing Cardiac Sequelae in Pediatric Cancer Survivors
3) Applying Biomarkers to Long-Term Effects in child and Adolescent Cancer Treatment
4) Early-Detection of Adverse Long-Term Treatment Effects in Childhood Leukemia Survivors
Speakers:
Shinya Ito, MD, FRCPC
Head, Division of Clinical Pharmacology/Toxicology, the Hospital for Sick Children
Professor, University of Toronto
Paul Nathan, MD, MSc, FRCPC
Director, AfterCare Program, The Hospital for Sick Children
Associate Professor, Pediatrics and Health Policy, Management & Evaluation, University of Toronto
Kirk R. Schulz, MD
Director, Childhood Cancer and Blood Research, BC Children’s Hospital and Child and Family Research Insittute, Michael Cuccione Childhood Cancer Research Program
Professor of Pediatrics, University of British Columbia
*NOTE – Kirk Schultz was unable to attend the Symposium. David Malkin (MD, FRCPC) presented his slides.
Daniel Sinnett, PhD
Professor, Department of Pediatrics, Université de Montréal
Research Scientist, Department of Hematology-Oncology, CHU Sainte-Justine Research Center